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Abstract 
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion 
who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran 
(150 mg b.i.d.). Coagulation parameters were normal (thrombin time 20 s, aPTT 20 s, INR 
1.08) and the patient improved from  an NIHSS of 15 to 5 within 24 h  with  sonographic 
evidence of M1 recanalization. She did not develop intracranial bleeding complications but 
showed unusually large diffuse skin ecchymoses. In our report, we give an overview of all 
reported cases of thrombolysis under dabigatran anticoagulation and discuss the questions 
of medication adherence under novel oral anticoagulants (NOA) and the safety of NOA in 
terms of secondary intracerebral hemorrhage after stroke. 
Introduction 
For more than 50 years, treatment with vitamin K antagonists had been the only thera-
peutic option to prevent strokes and other embolic events in patients with atrial fibrillation 
(AF).  In  2009,  three  large  phase  III  trials  of  three  novel  oral  anticoagulants,  the  direct 
thrombin  inhibitor  dabigatran  and  the  factor  Xa  inhibitors  rivaroxaban  and  apixaban, 
showed  non-inferiority  concerning  efficacy  and  safety  of  these  drugs  in  comparison  to 
warfarin. While the individual phase III trials of each of the novel oral anticoagulants (NOA)  
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were not powered to detect a difference in stroke risk or mortality, a meta-analysis of these 
trials (RE-LY [1], ROCKET-AF [2] and ARISTOTLE [3]) demonstrated a significant decrease of 
stroke risk and mortality under NOA in comparison to warfarin [4]. The most important 
benefits of the novel drugs in comparison to warfarin are their predictable pharmacokinetic 
profiles which render regular coagulation tests unnecessary and less pronounced drug-drug 
and  drug-food  interactions.  However,  they  are  problematic  in  situations  of  medical 
emergency, where a rapid assessment of the coagulation status is mandatory because they 
are not readily detected by standard coagulation tests [5]. 
Case Presentation 
We report the case of a 77-year-old woman with arterial hypertension and paroxysmal 
AF, who had been started on dabigatran 5 months before. In a telephone conversation with 
her daughter on a Sunday morning, she reported that she was doing fine but had experi-
enced palpitations two days earlier – and then suddenly fell silent. The immediately notified 
emergency  medical  services  found  a  confused  patient  with  global  aphasia,  brachiofacial 
paresis  of  the  right  side,  and  right  hemineglect.  The  NIHSS  upon  admission  fluctuated 
between 11 and 15 and CT scan showed early infarct signs in the left temporoparietal region, 
and a left hyperdense middle cerebral artery (MCA) sign (fig. 1a). CT angiography confirmed 
distal M1 occlusion (fig. 1b). The daughter, who reported that her mother independently and 
reliably  took  her  medication,  knew  of  a  ‘blood  pressure  tablet’  and  intermittent  use  of 
flecainide.  She  negated  warfarin,  ASA  or  any  alternative  blood  thinner.  Coagulation 
parameters were normal [thrombocytes 181/nl (140–440), INR 1.08 (<1.31), aPTT 20 (26–
36), thrombin time 20 (14–21)], and the creatinine level was slightly elevated at 1.0 mg/ml 
(0.4–0.9 mg/dl). Coagulation assays were performed with Thromborel S
® (INR), Pathrombin 
SL
® (aPTT) and BC Thrombin Reagent
® (thrombin time) on a BCS XP coagumeter (reagents 
and  coagumeter  from  Siemens  Healthcare  Diagnostics,  Marburg,  Germany).  The  patient 
received 60 mg rt-PA 1.5 h after symptom onset and rapidly improved to an NIHSS of 7. 
Later, a list of the patient’s current medication appeared which documented the prescription 
of dabigatran. The family doctor later confirmed this and estimated the patient’s medication 
adherence as good. The patient continued to improve functionally to an NIHSS of 5 within 
the next hours and CT follow-up the next day revealed an infarct in the anterior part of the 
MCA territory (fig. 1c). There was no sign of hemorrhagic transformation on MRI (fig. 1d, e), 
but the patient developed extended superficial ecchymoses of the whole body (fig. 1f, g), 
which  gradually  resolved  without  sequelae  over  two  weeks.  Duplex  sonography  after 
thrombolysis showed regular blood flow in the left MCA and moderate carotid atherosclero-
sis without relevant stenoses. We detected sinus rhythm in two subsequent ECGs. Transtho-
racic  echocardiography  found  no  structural  abnormalities  of  the  heart.  The  patient  was 
discharged to rehabilitative care on day 9 with an NIHSS of 4. Due to the large extent of the 
infarct, anticoagulation was not taken up during the initial hospitalization and the patient 
was discharged with ASA. We recommended the evaluation of tolerability and medication 
adherence during rehabilitation and to restart the patient accordingly on oral anticoagula-
tion. At three months’ follow-up, the patient was living independently at home with her 
husband. She showed no motor or sensory deficits but severe motor aphasia with fairly good 
speech comprehension. Nevertheless, she was not able to coherently state her medication 
adherence prior to her stroke. Her anticoagulation regime had been changed to rivaroxaban.  
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Discussion 
This  is  another  report  of  thrombolysis  for  stroke  under  oral  anticoagulation  with 
dabigatran without secondary intracerebral hemorrhage. For now, there are six case reports 
of thrombolysis in stroke under dabigatran treatment. In one additional case, the physicians 
abstained from thrombolysis because the last intake of 150 mg dabigatran was 2.5 h prior to 
stroke  onset  [6].  One  patient  with  several  risk  factors  for  hemorrhagic  transformation 
(diabetes mellitus with hyperglycemia upon presentation and a large perfusion deficit on 
CT) who received thrombolysis suffered a fatal secondary intracerebral hemorrhage after 
thrombolysis despite normal coagulation parameters [7]. Five other patients received rt-PA 
without intracranial hemorrhagic complications (table 1), but one patient also developed 
skin ecchymoses [8–12]. These cases indicate that thrombolysis might be safe if the aPTT is 
in  the  normal  range,  indicating  that  little  dabigatran  is  present.  Of  course,  general  risk 
factors for thrombolysis-associated hemorrhage as hyperglycemia, severe strokes and large 
perfusion deficits or extensive early infarct signs have to be taken into consideration. 
A stroke under anticoagulant therapy represents an ‘anticoagulation failure’. The most 
sensitive test to detect the presence of dabigatran is the thrombin time. In the case of our 
patient, the  normal  thrombin time clearly argues  for  the omission of at  least  one dose, 
because in the steady state a slight prolongation of the thrombin time should be expected 
even at trough level. Furthermore, the aPTT reagent used by our institution has been shown 
to be the most sensitive among three different commercially available aPTT reagents to 
detect dabigatran activity in a clinical trial of deep vein thrombosis prophylaxis after hip or 
knee surgery, still detecting a significant difference to trough concentrations at 12 h after 
220 mg Pradaxa in a once daily dosing regime [13 and E. Lindhoff-Last, personal communi-
cation]. A normal aPTT measured with this reagent further supports that the patient has 
most probably missed at least one dose. So far, there has been very little information on 
medication adherence under NOA. Interestingly, there was a significantly greater discontin-
uation rate in both dabigatran arms in comparison to the warfarin arm (21% and 21% vs. 
17%  after  2  years,  p  <  0.001)  in  the  RE-LY  trial  [1].  The  main  reasons  were  ‘patient’s 
decision’ and ‘gastrointestinal symptoms’. It can be assumed that these factors weigh even 
more  profoundly  on  medication  adherence  in  daily  clinical  practice  than  in  a  carefully 
selected study population with regular follow-up. Under warfarin treatment with regular 
coagulation monitoring, patients and physicians receive a regular feedback on medication 
adherence.  We  should  establish  similar  ‘check-ups’  under  NOA  treatment  to  assure 
medication adherence and evaluate comedications and undesired drug reactions. 
Interestingly, all cases of stroke under dabigatran reported so far do not show relevant 
alterations of the aPTT (table 1), which is the second sensitive standard coagulation assay 
that is influenced by dabigatran. Inadequate dosing for stroke prevention or omission of at 
least  one dose was  reported  in four of the seven cases  [6, 7, 10, 11]. It would  be very 
interesting to know the actual anticoagulant activity at the time of thrombolysis. Experi-
mental studies in murine stroke models have shown that effective dabigatran anticoagula-
tion with plasma levels up to 400 ng/ml does not lead to an increase in secondary intracere-
bral hemorrhage after rt-PA application [14] or to an increase of spontaneous HT in case of a 
continued [15] or early-initiated [16] anticoagulation after experimental stroke. Of course, 
these data from animal studies cannot be translated into clinical practice, but they point 
towards the possibility that NOA might be safer than warfarin in terms of intracerebral 
hemorrhage, especially after a stroke. One possible consequence might be the opportunity to 
start early anticoagulation after a cardioembolic stroke. To further explore this, it would be  
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of utmost interest to obtain the actual anticoagulant activity in patients who suffer a stroke 
under NOA. 
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Table 1. Synopsis of the seven published cases of stroke under dabigatran in the therapeutic time window 
                                       
Reference  Age 
years, 
sex 
Dabigatran indication 
and dose 
Interval 
last dose to 
thromboly-
sis 
NIHSS 
upon 
admis-
sion 
aPTT 
s 
INR  Thera-
peutic 
decision 
Outcome 
(NIHSS) 
Future 
OAC 
therapy 
                                       
De Smedt 
et al. [8] 
46, f  AF (RELY-ABLE 
extension study), dose 
not indicated, b.i.d. 
07 h  19  35  1.2  throm-
bolysis 
improvement 
(12 at dis-
charge) 
warfarin 
                                        Chong 
and Chiu 
[6] 
75, f  AF (RE-LY-trial), dose 
unknown, b.i.d., off 
dabigatran for 3 days in 
preparation for surgery 
i.n.a.  08  34  1.1  no 
throm-
bolysis 
improvement 
(2 at dis-
charge) 
n.i. 
                                        Matute 
et al. [9] 
76, f  DVT prophylaxis after 
surgery, 220 mg o.d. 
15 h  04  31  1.0  throm-
bolysis 
improvement 
(0 at dis-
charge) 
n.i. 
                                        Casado 
Naranjo 
et al. [7] 
62, m  AF, 110 mg b.i.d., 
patient not in steady 
state prior to stroke 
(3 doses) 
06 h  18  37  1.3  throm-
bolysis 
fatal 
intracerebral 
hemorrhage 
– 
                                        Sangha 
et al. [10] 
51, m  AF, 150 mg b.i.d.  18 h  06  31  1.1  throm-
bolysis 
improvement 
(2 at 6 
months) 
warfarin 
                                        Marrone 
and 
Marrone 
[11] 
73, m  AF, 110 mg b.i.d.  07 h  14  38  1.1  throm-
bolysis 
improvement 
(7 next day) 
dabigatran 
110 mg 
b.i.d. 
                                        Lee 
et al. [12] 
64, m  AF, i.n.a.  i.n.a.  i.n.a.  38  1.1  throm-
bolysis 
i.n.a., CCT: no 
hemorrhage 
i.n.a. 
                                       
o.d. = Once daily; b.i.d. = twice daily; i.n.a. = information not available; n.i. = not indicated. 
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Fig. 1. a Cranial CT on admission shows a hyperdense left MCA. b Distal left MCA occlusion was confirmed 
by  CT  angiography.  c  CT  follow-up  24  h  after  thrombolysis  showed  a  frontoparietal  MCA  infarction. 
d, e MRI without signs of gross hemorrhagic transformation. f, g Extended superficial ecchymoses of the 
skin after thrombolysis under dabigatran. 
 